
The authors presents the state of knowledge on the prevalence and proposed mechanisms leading to weight gain during treatment with atypical antipsychotics. A short review on the therapeutic approaches is also supplied.
Leptin, Dibenzothiazepines, Body Weight, Hyperlipidemias, Risperidone, Weight Gain, Piperazines, Quetiapine Fumarate, Thiazoles, Psychotic Disorders, Humans, Clozapine, Antipsychotic Agents
Leptin, Dibenzothiazepines, Body Weight, Hyperlipidemias, Risperidone, Weight Gain, Piperazines, Quetiapine Fumarate, Thiazoles, Psychotic Disorders, Humans, Clozapine, Antipsychotic Agents
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
